Axim Biotechnologies Ownership
| AXIM Stock | USD 0 0 50.00% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Axim |
Axim Pink Sheet Ownership Analysis
About 41.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.13. Axim Biotechnologies had not issued any dividends in recent years. AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California. Axim Biotechnologies operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 6 people.The quote for Axim Biotechnologies is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Axim Biotechnologies please contact John II at 858 923 4422 or go to https://www.aximbiotech.com.Axim Biotechnologies Outstanding Bonds
Axim Biotechnologies issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Axim Biotechnologies uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Axim bonds can be classified according to their maturity, which is the date when Axim Biotechnologies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US05464HAB69 Corp BondUS05464HAB69 | View | |
| AXIS SPECIALTY FIN Corp BondUS05464HAC43 | View | |
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US05463HAB78 Corp BondUS05463HAB78 | View | |
| US05463HAC51 Corp BondUS05463HAC51 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AYDEMT 775 02 FEB 27 Corp BondUS054644AA72 | View |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Axim Pink Sheet
Axim Biotechnologies financial ratios help investors to determine whether Axim Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Axim with respect to the benefits of owning Axim Biotechnologies security.